Daratumumab for heavily pretreated multiple myeloma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses the anti-CD38 monoclonal antibody, daratumumab, for the treatment of patients with pretreated multiple myeloma.